Tejara Capital’s Cullinan Oncology CGEM Stock Holding History

Tejara Capital’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-23,600	Closed	-$241K	–	80
2023 Q1	$241K	Hold	23,600	–	–	0.12%	73
2022 Q4	$249K	Buy	+23,600	New	+$287K	0.14%	84

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Tejara Capital's CGEM Position: Q2 2023 in Review

Tejara Capital sold out of Cullinan Oncology (CGEM) in Q2 2023, closing a stake of 23,600 shares — an estimated $241K sold.

Tejara Capital first reported a position in CGEM in Q4 2022 and held it in 2 quarters. The position peaked at $249K in Q4 2022. 106 funds tracked by Wall St. Rank hold CGEM as of Q2 2023.

Tejara Capital reported no remaining Cullinan Oncology position as of Q2 2023 after selling out during the quarter.
Tejara Capital sold 23,600 Cullinan Oncology shares in Q2 2023, an estimated $241K.
Tejara Capital first reported a position in Cullinan Oncology in Q4 2022 and held it in 2 quarters.
Tejara Capital's Cullinan Oncology position peaked at $249K in Q4 2022.
106 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2023.

Based on Tejara Capital's 13F filing for Q2 2023, filed 11 Aug 2023.